Ongoing phase II clinical studies (NCT03267316 and NCT05116891) on IL-1RAcP antibody CAN04, which showed the potency of selective cytokine signaling inhibition of IL-1 family cytokines in NSCLC (62), may hopefully find a new method to treat lung cancer. This evidence concerns the gene IL1B and lung carcinoma.